Gene info: ID 4487

Gene: MSX1

GENE ID: 4487

Synonyms: ECTD3|HOX7|HYD1|STHAG1

Description: msh homeobox 1

Gene type: protein-coding

Location: 4p16.2

dbXrefs: Ensembl:ENSG00000163132 MIM:142983 Vega:OTTHUMG00000090335 UniprotKB:P28360

RefSeq: NG_008121.1

Retrived from: PubMed

SNPs: 0 ANCO-SNPs

Phenotype: ND

# Publications: 11

Sherlock p-value : NA (AD) NA (ND) (Frontal_Cortex)

Pascal p-value : 8.411e-1 (AD) 1.651e-1 (ND)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol	Pearson Correlation Coefficient
TFAP2C	0.747
TCF7L1	0.732
ITGB5	0.722
EFNB1	0.712
PLCB3	0.698
ZIC2	0.689
EVC2	0.688
TMEM51	0.682
GRTP1	0.682
EYA2	0.68

Top 10 negatively co-expressed genes

Gene Symbol	Pearson Correlation Coefficient
NRG1	-0.543
CHRM2	-0.518
FOXP2	-0.506
ADTRP	-0.499
FSTL4	-0.498
RASGRP1	-0.497
HMGCLL1	-0.497
AK7	-0.492
OCA2	-0.49
RYR2	-0.487

There is no DrugBank record for this gene !

ID	Drug Name	Action	PubMed
C111118	2',3,3',4',5-pentachloro-4-hydroxybiphenyl	"2',3,3',4',5-pentachloro-4-hydroxybiphenyl results in decreased expression of MSX1 mRNA"	19114083
C006551	2-amino-2-methyl-1-propanol	2-amino-2-methyl-1-propanol results in decreased expression of MSX1 mRNA	25088246
C459179	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	"[NOG protein co-treated with belinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MSX1 mRNA"	27188386
C459179	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	"[NOG protein co-treated with mercuric bromide co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MSX1 mRNA"	27188386
C459179	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MSX1 mRNA"	27188386
C459179	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	"[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MSX1 mRNA"	27188386
C459179	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MSX1 mRNA"	27188386
C459179	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MSX1 mRNA"	27188386
C459179	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MSX1 mRNA"	27188386
C459179	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	"[NOG protein co-treated with vorinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MSX1 mRNA"	27188386
C516138	(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine	"[NOG protein co-treated with belinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MSX1 mRNA"	27188386
C516138	(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine	"[NOG protein co-treated with mercuric bromide co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MSX1 mRNA"	27188386
C516138	(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine	"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MSX1 mRNA"	27188386
C516138	(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine	"[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MSX1 mRNA"	27188386
C516138	(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine	"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MSX1 mRNA"	27188386
C516138	(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine	"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MSX1 mRNA"	27188386
C516138	(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine	"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MSX1 mRNA"	27188386
C516138	(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine	"[NOG protein co-treated with vorinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MSX1 mRNA"	27188386
D000082	Acetaminophen	Acetaminophen results in increased expression of MSX1 mRNA	21420995\|2906747
D016604	Aflatoxin B1	Aflatoxin B1 affects the expression of MSX1 protein	20106945
D000643	Ammonium Chloride	Ammonium Chloride affects the expression of MSX1 mRNA	16483693
D018501	Antirheumatic Agents	Antirheumatic Agents results in increased expression of MSX1 mRNA	24449571
D001151	Arsenic	Arsenic results in increased methylation of MSX1 promoter	21291286
C015001	arsenite	arsenite results in increased methylation of MSX1 promoter	23974009
C487081	belinostat	belinostat results in increased expression of MSX1 mRNA	26272509
C487081	belinostat	"[NOG protein co-treated with belinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MSX1 mRNA"	27188386
C006780	bisphenol A	bisphenol A affects the methylation of MSX1 promoter	27334623
C006780	bisphenol A	bisphenol A results in increased expression of MSX1 mRNA	25181051
D002104	Cadmium	Cadmium results in decreased expression of MSX1 mRNA	23256528
D002220	Carbamazepine	Carbamazepine affects the expression of MSX1 mRNA	25979313
C084597	chlorcyclizine	chlorcyclizine results in increased expression of MSX1 mRNA	21058326
D020245	p-Chloromercuribenzoic Acid	"[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MSX1 mRNA"	27188386
D020245	p-Chloromercuribenzoic Acid	p-Chloromercuribenzoic Acid results in increased expression of MSX1 mRNA	26272509
D002794	Choline	[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased methylation of MSX1 gene	20938992
C007076	citral	citral results in decreased expression of MSX1 mRNA	15581867
D019327	Copper Sulfate	Copper Sulfate results in increased expression of MSX1 mRNA	19549813
D003471	Cuprizone	Cuprizone results in increased expression of MSX1 mRNA	26577399
D016572	Cyclosporine	Cyclosporine results in increased expression of MSX1 mRNA	20106945
C093628	cyproconazole	cyproconazole results in decreased expression of MSX1 mRNA	22045034
D003561	Cytarabine	Cytarabine results in decreased expression of MSX1 mRNA	21198554
D003634	DDT	DDT results in decreased expression of MSX1 mRNA	19797855
C014347	decitabine	decitabine results in increased expression of MSX1 mRNA	16367923
D003907	Dexamethasone	Dexamethasone results in decreased expression of MSX1 mRNA	28453788
C036042	dicyclohexyl phthalate	dicyclohexyl phthalate results in decreased expression of MSX1 mRNA	26924002
D004040	Dietary Carbohydrates	Dietary Carbohydrates results in increased expression of MSX1 mRNA	17490981
D004051	Diethylhexyl Phthalate	Diethylhexyl Phthalate results in increased expression of MSX1 mRNA	28412506
C472511	dimethylarsinous acid	dimethylarsinous acid results in decreased expression of MSX1 protein	26024302
C024629	dimethyl phthalate	dimethyl phthalate results in decreased expression of MSX1 mRNA	26924002
D004237	Diuron	Diuron results in decreased expression of MSX1 mRNA	25152437
C118739	entinostat	entinostat results in increased expression of MSX1 mRNA	26272509
D000431	Ethanol	Ethanol results in decreased expression of MSX1 mRNA	28919490
D005419	Flavonoids	Flavonoids results in increased expression of MSX1 mRNA	18035473
D005492	Folic Acid	[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased methylation of MSX1 gene	20938992
D005557	Formaldehyde	Formaldehyde results in increased expression of MSX1 mRNA	20655997
C039281	furan	furan results in decreased expression of MSX1 mRNA	25539665
C409722	hexaconazole	hexaconazole results in decreased expression of MSX1 mRNA	22045034
C042720	mercuric bromide	mercuric bromide results in increased expression of MSX1 mRNA	26272509
C042720	mercuric bromide	"[NOG protein co-treated with mercuric bromide co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MSX1 mRNA"	27188386
D008715	Methionine	[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased methylation of MSX1 gene	20938992
D008767	Methylmercury Compounds	Methylmercury Compounds results in increased expression of MSX1 mRNA	21664453
C091888	monoisoamyl-2,3-dimercaptosuccinate	"monoisoamyl-2,3-dimercaptosuccinate inhibits the reaction [sodium arsenite results in decreased expression of MSX1 mRNA]"	19615344
C091888	monoisoamyl-2,3-dimercaptosuccinate	"monoisoamyl-2,3-dimercaptosuccinate results in decreased expression of MSX1 mRNA"	19615344
C406082	monomethylarsonous acid	monomethylarsonous acid results in decreased expression of MSX1 mRNA	26024302
C406082	monomethylarsonous acid	monomethylarsonous acid results in decreased expression of MSX1 protein	26024302
C517284	monomethyl phthalate	monomethyl phthalate results in decreased expression of MSX1 mRNA	26924002
D009538	Nicotine	Nicotine results in increased expression of MSX1 mRNA	20339300
C496932	panobinostat	"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MSX1 mRNA"	27188386
C496932	panobinostat	panobinostat results in increased expression of MSX1 mRNA	26272509
C568608	PCI 5002	[PCI 5002 co-treated with Zinc] results in increased expression of MSX1 mRNA	18593933
D010634	Phenobarbital	Phenobarbital affects the expression of MSX1 mRNA	19159669
D010662	Phenylmercuric Acetate	"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MSX1 mRNA"	27188386
D010662	Phenylmercuric Acetate	Phenylmercuric Acetate results in increased expression of MSX1 mRNA	26272509
D010938	Plant Oils	Plant Oils results in increased expression of MSX1 mRNA	23370395
D011374	Progesterone	Progesterone results in decreased expression of MSX1 mRNA	23018184
C513428	pyrachlostrobin	pyrachlostrobin results in increased expression of MSX1 mRNA	27029645
D011794	Quercetin	Quercetin results in decreased expression of MSX1 mRNA	21632981
D011794	Quercetin	Quercetin results in decreased expression of MSX1 protein	28431985
C009166	retinol acetate	retinol acetate results in increased expression of MSX1 mRNA	16772331
C115461	SC 560	SC 560 results in decreased expression of MSX1 mRNA	14633654
C115461	SC 560	SC 560 results in decreased expression of MSX1 protein	14633654
D012834	Silver	Silver results in increased expression of MSX1 mRNA	26551752
D012834	Silver	Silver results in increased expression of MSX1 mRNA	27131904
C017947	sodium arsenite	"monoisoamyl-2,3-dimercaptosuccinate inhibits the reaction [sodium arsenite results in decreased expression of MSX1 mRNA]"	19615344
C017947	sodium arsenite	sodium arsenite results in decreased expression of MSX1 mRNA	19615344
C017947	sodium arsenite	sodium arsenite results in decreased expression of MSX1 mRNA	26024302
C017947	sodium arsenite	sodium arsenite results in decreased expression of MSX1 protein	26024302
C025462	sulindac sulfide	sulindac sulfide results in decreased expression of MSX1 mRNA	12734198
C025462	sulindac sulfide	sulindac sulfide results in decreased expression of MSX1 protein	12734198
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin affects the expression of MSX1 mRNA	24058054
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin promotes the reaction [tributyltin results in decreased expression of MSX1 mRNA]	22749964
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin results in decreased expression of MSX1 mRNA	16922920\|1758670
D014212	Tretinoin	Tretinoin results in increased expression of MSX1 mRNA	17138961\|2193413
D014212	Tretinoin	Tretinoin results in increased expression of MSX1 mRNA	16604517
C011559	tributyltin	Tetrachlorodibenzodioxin promotes the reaction [tributyltin results in decreased expression of MSX1 mRNA]	22749964
C011559	tributyltin	tributyltin results in decreased expression of MSX1 mRNA	22749964
C012589	trichostatin A	"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MSX1 mRNA"	27188386
C012589	trichostatin A	trichostatin A results in increased expression of MSX1 mRNA	24935251\|2627250
C015559	trimellitic anhydride	trimellitic anhydride results in decreased expression of MSX1 mRNA	19042947
C057693	troglitazone	troglitazone results in increased expression of MSX1 mRNA	19140230
D014520	Urethane	Urethane results in increased expression of MSX1 mRNA	28818685
D014635	Valproic Acid	"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MSX1 mRNA"	27188386
D014635	Valproic Acid	Valproic Acid affects the expression of MSX1 mRNA	25979313
D014635	Valproic Acid	Valproic Acid results in decreased expression of MSX1 mRNA	28001369
D014635	Valproic Acid	Valproic Acid results in increased expression of MSX1 mRNA	23179753\|2438349
D014635	Valproic Acid	Valproic Acid results in decreased expression of MSX1 mRNA	19136453\|2204503
D001335	Vehicle Emissions	Vehicle Emissions affects the methylation of MSX1 gene	25560391
C111237	vorinostat	"[NOG protein co-treated with vorinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MSX1 mRNA"	27188386
C111237	vorinostat	vorinostat results in increased expression of MSX1 mRNA	26272509
D015032	Zinc	[PCI 5002 co-treated with Zinc] results in increased expression of MSX1 mRNA	18593933

GO/Pathway

GO ID	GO Term	Qualifier	Evidence	PubMed
GO:0000977	RNA polymerase II regulatory region sequence-specific DNA binding	-	IEA	-
GO:0000981	RNA polymerase II transcription factor activity, sequence-specific DNA binding	-	ISA	-
GO:0000981	RNA polymerase II transcription factor activity, sequence-specific DNA binding	-	ISM	19274049
GO:0000981	RNA polymerase II transcription factor activity, sequence-specific DNA binding	-	NAS	19274049
GO:0000982	transcription factor activity, RNA polymerase II proximal promoter sequence-specific DNA binding	-	IEA	-
GO:0001227	transcriptional repressor activity, RNA polymerase II transcription regulatory region sequence-specific DNA binding	-	IEA	-
GO:0001228	transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific DNA binding	-	IEA	-
GO:0002039	p53 binding	-	IPI	15705871
GO:0035326	enhancer binding	-	IEA	-

GO ID	GO Term	Qualifier	Evidence	PubMed
GO:0000122	negative regulation of transcription by RNA polymerase II	-	IEA	-
GO:0000902	cell morphogenesis	-	IDA	15705871
GO:0001701	in utero embryonic development	-	IEA	-
GO:0003198	epithelial to mesenchymal transition involved in endocardial cushion formation	-	IEA	-
GO:0006366	transcription by RNA polymerase II	-	IEA	-
GO:0007517	muscle organ development	-	IEA	-
GO:0008285	negative regulation of cell proliferation	-	IEA	-
GO:0009952	anterior/posterior pattern specification	-	IEA	-
GO:0010463	mesenchymal cell proliferation	-	IEA	-
GO:0021983	pituitary gland development	-	IEA	-
GO:0023019	signal transduction involved in regulation of gene expression	-	IEA	-
GO:0030308	negative regulation of cell growth	-	IDA	15705871
GO:0030513	positive regulation of BMP signaling pathway	-	IEA	-
GO:0030901	midbrain development	-	IEA	-
GO:0034504	protein localization to nucleus	-	IDA	15705871
GO:0035115	embryonic forelimb morphogenesis	-	IEA	-
GO:0035116	embryonic hindlimb morphogenesis	-	IEA	-
GO:0035880	embryonic nail plate morphogenesis	-	IMP	11369996
GO:0042474	middle ear morphogenesis	-	IEA	-
GO:0042475	odontogenesis of dentin-containing tooth	-	IMP	8696335 10742093 11369996
GO:0042481	regulation of odontogenesis	-	IEA	-
GO:0043066	negative regulation of apoptotic process	-	IEA	-
GO:0043517	positive regulation of DNA damage response, signal transduction by p53 class mediator	-	IC	15705871
GO:0045944	positive regulation of transcription by RNA polymerase II	-	IEA	-
GO:0048863	stem cell differentiation	-	IEA	-
GO:0050821	protein stabilization	-	IDA	15705871
GO:0051154	negative regulation of striated muscle cell differentiation	-	IEA	-
GO:0060021	roof of mouth development	-	IEA	-
GO:0060325	face morphogenesis	-	IMP	10742093 11332647 12651933
GO:0060349	bone morphogenesis	-	IEA	-
GO:0060536	cartilage morphogenesis	-	IEA	-
GO:0061180	mammary gland epithelium development	-	IEA	-
GO:0061312	BMP signaling pathway involved in heart development	-	IEA	-
GO:0071316	cellular response to nicotine	-	IEA	-
GO:0090427	activation of meiosis	-	IEA	-
GO:1902255	positive regulation of intrinsic apoptotic signaling pathway by p53 class mediator	-	IDA	15705871
GO:2000678	negative regulation of transcription regulatory region DNA binding	-	IEA	-
GO:2001055	positive regulation of mesenchymal cell apoptotic process	-	IEA	-

GO ID	GO Term	Qualifier	Evidence	PubMed
GO:0005634	nucleus	-	IDA	15705871
GO:0005654	nucleoplasm	-	IDA	-

KEGG ID	KEGG Term

Reactome ID	Reactome Term	Evidence

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID	Title (Year)	Author	Journal
9988882	Candidate genes for nonsyndromic cleft lip and palate and maternal cigarette smoking and alcohol consumption: evaluation of genotype-environment interactions from a population-based case-control study of orofacial clefts. (1999 Jan)	Romitti PA	Teratology
14994238	Limb deficiency defects, MSX1, and exposure to tobacco smoke. (2004 Mar 15)	Carmichael SL	Am J Med Genet A
18218836	Unraveling human cleft lip and palate research. (2008 Feb)	Vieira AR	J Dent Res
9482651	Association between homeobox-containing gene MSX1 and the occurrence of limb deficiency. (1998 Feb 3)	Hwang SJ	Am J Med Genet
18698632	Genetic susceptibilities in the association between maternal exposure to tobacco smoke and the risk of nonsyndromic oral cleft. (2008 Sep 15)	Chevrier C	Am J Med Genet A
15965987	Evaluation of two methods for assessing gene-environment interactions using data from the Danish case-control study of facial clefts. (2005 Aug)	Etheredge AJ	Birth Defects Res A Clin Mol Teratol
27996298	Genetic Interactions in Nonsyndromic Orofacial Clefts in Europe-EUROCRAN Study. (2017 Nov)	Mossey PA	Cleft Palate Craniofac J
11454503	A case-control study of nonsyndromic oral clefts in Maryland. (2001 Aug)	Beaty TH	Ann Epidemiol
27356075	Associations Between TGFA/TGFB3/MSX1 Gene Polymorphisms and Congenital Non-Syndromic Hearing Impairment in a Chinese Population. (2016 Jun 29)	Du J	Med Sci Monit
11754469	Testing candidate genes for non-syndromic oral clefts using a case-parent trio design. (2002 Jan)	Beaty TH	Genet Epidemiol
12916025	Family-based analysis of MSX1 haplotypes for association with oral clefts. (2003 Sep)	Fallin MD	Genet Epidemiol